Juvaris BioTherapeutics, Inc. Company Profile

News Articles [ 203 Associated News Articles listed on BioPortfolio]

Smith & Nephew acquires Healthpoint Biotherapeutics for $782 million

Smith & Nephew has signed an agreement to acquire substantially all of the assets of Healthpoint Biotherapeutics for $782 million in cash. Healthpoint Biotherapeutics has been focused on biopharma...

Data from Eleven Biotherapeutics' EBI-005 preclinical study on ocular diseases

Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics, has published preclinical data in Proceedings of the National Academy of Sciences (...

Valor, Oxygen Biotherapeutics enter License and Supply Agreement for Dermacyte

Oxygen Biotherapeutics, Inc., announced today that it has entered into a License and Supply Agreement with the Cosmetics Division of Valor SA of Lausanne, Switzerland, for Dermacyte, a perfluorocarbon...

[Northwest Biotherapeutics] nets $9.3mm through RDO

Cancer immunotherapeutics company [Northwest Biotherapeutics Inc.] netted $9.3mm through a registered direct offering. An undisclosed

How to select the best candidate for biotherapeutics drug development

Antibodies, antibody-like proteins, and other biotherapeutics represent a large and growing number of molecular entities entering human clinical trials in virtually all disease indications. The [...]

Menarini and Oxford BioTherapeutics ink $1 billion cancer pact

Menarini and Oxford BioTherapeutics announce a major innovative and strategic alliance to develop a portfolio of antibody-based drugs in the field of cancer.The agreement covers five of antibody and a...

[Beat BioTherapeutics] gets seeded with $2.5mm

CET Capital Partners, the W Fund, and 19 other undisclosed investors have seeded gene therapy firm [Beat BioTherapeutics Corp.] with $2.5mm through the sale of debt. CET will contribute one board memb...

NW Bio appoints vet Rosskamp as CEO of German subsidiary

Northwest Biotherapeutics, a biotech developing DCVaxR personalized immune therapies for cancer, has appointed former pharmaceutical industry executive Dr. Gunter Rosskamp as the CEO of the company's...

Drugs and Medications [ 14 Associated Drugs and Medications listed on BioPortfolio]

Plasmanate [TALECRIS BIOTHERAPEUTICS, INC.]

Plasma Protein Fraction (Human) 5%, USPPlasmanate®

Gamastan s/d [TALECRIS BIOTHERAPEUTICS, INC.]

Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 20%, USPPlasbumin®-20

PubMed Articles [ 20 Associated PubMed Articles listed on BioPortfolio]

Coupling of Aggregation and Immunogenicity in Biotherapeutics: T- and B-Cell Immune Epitopes May Contain Aggregation-Prone Regions.

Biotherapeutics, including recombinant or plasma-derived human proteins and antibody-based molecules, have emerged as an important class of pharmaceuticals. Aggregation and immunogenicity are among th...

Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration.

The subcutaneous (SC) route is of growing interest for the administration of biotherapeutics. Key products on the biotherapeutic market such as insulins, but also several immunoglobulins or Fc-fusion...

Subcutaneous administration of biotherapeutics: Current experience in animal models.

In recent years, many peptide- and protein-based biotherapeutics have been approved for subcutaneous (SC) delivery. The mechanisms and factors affecting the uptake and distribution of such large molec...

Protein Particulate Detection Issues in Biotherapeutics Development-Current Status.

Formation of aggregates and particulates in biopharmaceutical formulation continues to be one of the major quality concerns in biotherapeutics development. The presence of large quantities of aggregat...

Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics.

An immune response to a biotherapeutic can be induced when the therapeutic is processed and presented by antigen presenting cell to T helper cells. This study evaluates the performance of an in vitro...

Clinical Trials [ 1 Associated Clinical Trials listed on BioPortfolio]

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...

Companies [ 61 Associated Companies listed on BioPortfolio]

Juvaris BioTherapeutics, Inc

Juvaris BioTherapeutics is a clinical stage company developing adjuvanted vaccines to treat infectious diseases. The Company’s lead adjuvant, JVRS-100, is a cationic l...

Juvaris BioTherapeutics, Inc.

Juvaris is a virtual biotech company with licensees advancing its Cationic Lipid-DNA Complex (CLDC) technology to develop adjuvanted vaccines and immunotherapeutics to treat infec...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent...

Talecris Biotherapeutics Holdings Inc.

Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders i...

Talecris Biotherapeutics, Inc.

Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-th...